The intermittent intrapulmonary deflation technique for airway clearance in patients with cystic fibrosis: A randomized trial.

Airway clearance technique Cystic fibrosis Intermittent intrapulmonary deflation Mucus and sputum Rheology Simeox

Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
29 Feb 2024
Historique:
received: 22 02 2023
revised: 04 12 2023
accepted: 25 02 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 6 6 2024
Statut: aheadofprint

Résumé

Cystic fibrosis (CF) is a muco-obstructive lung disease characterized by thick sputum with abnormal rheological properties. The intermittent intrapulmonary deflation (IID) is a new instrumental airway clearance technique (ACT) that aims to decrease the sputum viscoelastic properties. This study assessed the benefits of adding the IID technique to a conventional ACT in patients with CF hospitalized for intravenous antibiotic therapy. Participants with CF accustomed to autogenic drainage (AD) as their standard ACT received, in a randomized order, a 30-min session of either AD alone or AD combined with IID (AD+IID). Sputum was collected during each ACT regimens and for a 24-hour period following both sessions. Sputum wet weight, dry weight, solids content and rheological properties were analyzed. Cough events occurring during and over 2 h post ACT were compared between both regimens. Seventeen patients with CF (aged 29 ± 11 years; FEV In participants with CF accustomed to AD, adding the IID technique in combination to AD does not confer a clear benefit on airway clearance in the short term. Clinical Trials register: NCT04157972.

Sections du résumé

BACKGROUND BACKGROUND
Cystic fibrosis (CF) is a muco-obstructive lung disease characterized by thick sputum with abnormal rheological properties. The intermittent intrapulmonary deflation (IID) is a new instrumental airway clearance technique (ACT) that aims to decrease the sputum viscoelastic properties. This study assessed the benefits of adding the IID technique to a conventional ACT in patients with CF hospitalized for intravenous antibiotic therapy.
METHODS METHODS
Participants with CF accustomed to autogenic drainage (AD) as their standard ACT received, in a randomized order, a 30-min session of either AD alone or AD combined with IID (AD+IID). Sputum was collected during each ACT regimens and for a 24-hour period following both sessions. Sputum wet weight, dry weight, solids content and rheological properties were analyzed. Cough events occurring during and over 2 h post ACT were compared between both regimens.
RESULTS RESULTS
Seventeen patients with CF (aged 29 ± 11 years; FEV
CONCLUSIONS CONCLUSIONS
In participants with CF accustomed to AD, adding the IID technique in combination to AD does not confer a clear benefit on airway clearance in the short term. Clinical Trials register: NCT04157972.

Identifiants

DOI: 10.1016/j.resmer.2024.101094 PMID: 38843595
pubmed: 38843595
pii: S2590-0412(24)00011-4
doi: 10.1016/j.resmer.2024.101094
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04157972']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101094

Informations de copyright

Copyright © 2024 SPLF and Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest PhysioAssist company provided the device used in this study (Simeox) free of charge and supported financially the study. The study was performed at Cliniques universitaires Saint-Luc - Avenue Hippocrate, 10 - 1200 - Brussels – Belgium

Auteurs

Juliana Ribeiro Fonseca Franco de Macedo (JRFF)

Institute de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Service de Pneumologie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Secteur de Kinésithérapie et Ergothérapie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium. Electronic address: demacedo.franco@gmail.com.

Anne-Sophie Aubriot (AS)

Institute de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Secteur de Kinésithérapie et Ergothérapie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Centre de Référence pour la Mucoviscidose, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Gregory Reychler (G)

Institute de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Service de Pneumologie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Secteur de Kinésithérapie et Ergothérapie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium.

Morgane Penelle (M)

Institute de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Secteur de Kinésithérapie et Ergothérapie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Centre de Référence pour la Mucoviscidose, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Sophie Gohy (S)

Institute de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Service de Pneumologie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Centre de Référence pour la Mucoviscidose, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

William Poncin (W)

Institute de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL & Dermatologie, Université Catholique de Louvain, 1200 Brussels, Belgium; Service de Pneumologie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium; Secteur de Kinésithérapie et Ergothérapie, Cliniques universitaires Saint-Luc, 1200 Brussels, Belgium.

Classifications MeSH